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Abstract
Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently
there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In
the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing
agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A
model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays
the disease onset and improves motor performance in ALS mice. Although we were not
able to demonstrate the mechanistic basis of the beneficial 5-FU action in ALS mice, our
findings suggest that 5-FU or similar drugs are possible drug candidates for the treatment of
motor neuron diseases through drug repurposing.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating disease characterized by upper and lower
motor neuron (MN) degeneration, progressive muscle paralysis and atrophy [1]. ALS patients
typically die from cardiorespiratory failure within 2–5 years after the diagnosis. The only FDA
accepted treatments for ALS, riluzole and edaravone, appear to provide only limited benefit to
the patients. Thus, new treatments are desperately needed for fighting ALS [2]. While new
drugs, cell-based therapies and gene targeting are being investigated for clinical use, the prog-
ress is slow because of bottlenecks in the therapeutic development process. Drug repurposing
(using an agent already commercialized to treat one disease for the treatment of other diseases)
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is one of the strategies to reduce the time required to get new treatments on the market.
Because repurposing is built on previous R&D efforts, their review by the regulatory agencies
is accelerated and new candidate therapies may reach clinical trials and integrate into the clinic
more quickly. Several well-known drugs commercialized for other diseases are being investi-
gated in the search for ALS treatment and some of them have already reached clinical trials
[3].
In the search for drug candidates for ALS treatment, we have recently studied stem cell
mobilizing agents, some of which have been shown to positively affect the outcome in the
SOD1G93A model of ALS [4–7]. As an additional “control” treatment that we reasoned to
have an opposite (i.e. temporary negative) effect on circulating hematopoietic stem cells and
white blood cell (WBC) count, we used low dose of the well characterized, FDA-approved
anti-cancer drug 5-fluorouracil (5-FU). The principal known action of 5-FU is inhibition of
DNA synthesis by blocking the activity of thymidylate synthase (TYMS, EC 2.1.1.45) which
causes an imbalance of the nitrogen bases normally used for DNA synthesis and misincorpora-
tion of uracil into DNA [8]. Although less studied, 5-FU can also induce striking alterations in
RNA metabolism, such as impairments in messenger RNA (mRNA) and ribosomal RNA
(rRNA) synthesis, splicing and post-transcriptional modification [9, 10]. Because 5-FU toxicity
is related with cell division, cells with higher replicative rate (such as cancer cells, hematopoi-
etic cells and intestinal enterocytes) are more sensitive to the drug.
As expected, we observed a temporary decrease in WBC and hematopoietic stem cells after
5-FU administration which was fully recovered within two weeks of the treatment. Against
our initial hypothesis, we also found that, instead of aggravating the disease in SOD1G93A
mice, 5-FU increased the lifespan of the treated animals, delayed the disease onset and
improved the motor performance measured by rotarod test. Although 5-FU did not signifi-
cantly modulate motor neuron survival, reactive gliosis or muscle morphology our results sug-
gest that a low-dose regimen of 5-FU or its analogs may have beneficial effects on ALS and
encourage further pharmacological and mechanistic studies for their use as repurposed ALS
drugs.
Material and methods
Animals
All procedures were approved by the Ethic Committee for Animal Experimentation of the
University of Zaragoza (permisson number PI18/17). Animals were taken care according to
the Spanish Policy for Animal Protection RD53/2013 and the EU Directive 2010/63. The trans-
genic mice B6SJLTg(SOD1G93A)1Gur/J [11] expressing a high copy number of the G93A
mutant form of human SOD1 were purchased from The Jackson Laboratory and housed in
the animal facilities of the UZ. Food and water were available ad libitum. SOD1G93A colony
was maintained by breeding hemizygous SOD1G93A males with B6SJL wild-type females. The
genotyping of the offspring was performed as described in the in the Jackson Laboratory pro-
tocol. The animals were maintained in conditions of environmental enrichment (such as
paper rolls) and were examined daily to avoid suffering. The humane endpoint for experimen-
tal animals was established as the moment the mice were unable to right themselves within 30
seconds after being placed on their side and the age at this moment was considered as death
for survival analysis [12]. Animals were euthanized individually with CO2.
Administration of 5-FU
To determine the effect of 5-FU on blood cell counts, ten SOD1G93A mice at age of 10 weeks
were subjected to a single intraperitoneal injection of 5-FU at 150 mg/kg. The drug was freshly
5-FU improves ALS mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0210752 January 14, 2019 2 / 16
funds from the Instituto de Salud Carlos III of
Spain (XN), and Fondazione Roma and Agenzia
Spaziale Italiana (AM). The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: We have read the journal’s
policy and the authors of this manuscript have the
following competing interests: Patent (RO, AR,
JMT, PZ, AM) titled “Composiciones para el
tratamiento de las enfermedades de las
motoneuronas” (Compositions for the treatment of
motor neurone diseases). Priority number:
P201431825 (ES), 11 December 2014. This does
not alter our adherence to PLOS ONE policies on
sharing data and materials.
diluted in saline (15 mg/ml) and the volume of each individual injection was between 0.18 and
0.32 ml. For the behavioural tests, survival assay and serial blood extractions to determine the
evolution in the number of hematopoietic stem cells (see below), SOD1G93A mice were
injected as with 5-FU or with saline every two weeks (age of 10, 12 and 14 weeks). This fort-
nightly dose corresponds to a low dose of 12.2 mg/kg, or 450 mg/m2, in humans [13]. The total
number of mice used for survival assay was 58 (29 treated with 5-FU and 29 with saline), of
which 22 were also used for behavioural assays (11 treated with 5-FU and 11 with saline). Serial
blood sampling was conducted on 20 mice (10 treated with 5-FU and 10 with saline).
Cell counts in peripheral blood and the bone marrow
Blood and bone marrow were collected before the treatment (t = 0, n = 4) and at days 4
(n = 4), 14 (n = 4) and 20 (n = 2) after the single 5-FU injection and compared with basal con-
ditions (t = 0). Briefly, blood was extracted by cardiac puncture and 100 μl of total blood cells
were quantified (cells per ml) by ABACUS Junior Vet Hematology Analyzer (Diatron). From
each mouse, the bone marrow from both femurs was obtained by flushing the medullary cavity
with phosphate buffered saline (PBS). Suspended bone marrow cells were stained with Quick
Panoptic kit (Analytix), centrifuged 400 x g for 5 min and resuspended in 1% bovine serum
albumin (BSA) in PBS. After treatment with erythrocyte lysis buffer (Sigma-Aldrich) samples
were centrifuged as above and the bone marrow mononuclear cells (BMMC) were counted
and expressed as BMMC per femur.
Serial blood extractions and hematopoietic stem cell determination
Before the first 5-FU administration (day 65) and five days after every injection (days 75, 90
and 105), blood samples were extracted from the tail vein to analyze the effect of 5-FU admin-
istration on circulating hematopoietic stem cells. Blood samples were collected and prepared
for immunostaining as previously described [7] and incubated for 30 minutes with following
antibodies: anti-mouse Ly-6A/E (Sca-1) PE (12–5981 eBioscience), anti-mouse CD117 (c-Kit)
APC (17–1171 eBioscience), mouse hematopoietic lineage eFluor 450 Cocktail (eBioscience
88–7772) and PE-Cy7 rat anti-mouse CD127 (560733 BD Biosciences). The number of
hematopoietic stem cells (HSCs; lin-, Sca-1 +, c-kit +), common myeloid progenitors (CMPs;
lin-, Sca-1 -, c-kit +), and common lymphoid progenitors (CLPs; Lin-, CD127+) were deter-
mined using a Gallios flow cytometer (Beckman Coulter) and the output was analyzed with
Kaluza software (Beckman Coulter). The data were expressed as a percentage of the total
selected events.
Behavioral tests
Two sex balanced groups of SOD1G93A mice (n = 11 per group) were randomly distributed
to evaluate the progression of the disease and locomotor function by rotarod and hang-wire
tests. Starting at the age of ten weeks (before the first injection), these tests were performed
weekly until the mice reached the endpoint criteria following the international guidelines for
preclinical studies with ALS mice [14]. In the rotarod test, the time mice were able to maintain
their balance on the wheel was recorded. For assessing muscle strength, the mice were placed
on a wire lid, gently turned upside down and the latency to fall was timed. In both tests, ani-
mals were given three opportunities to reach a maximum of 180 seconds and only the best per-
formance was considered. Weight of each animal was recorded weekly and the onset of the
disease for each animal was assed at the moment the particular mouse did not increase in
weight any more.
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Gene expression
At the age of 15 weeks (five days after the last injection), plasma and skeletal muscle from
5-FU treated or vehicle treated SOD1G93A mice, as well as wild-type littermates (n = 8 for all
groups), were collected and processed for gene expression analysis. Left quadriceps femoris
muscles were dissected and immediately frozen in liquid nitrogen. Each muscle was pulverized
in liquid nitrogen using a Cellcrusher cryogenic tissue pulverizer (Cellcrusher, Cork, Ireland)
and half of the power was kept at -80˚C for protein extraction (below). The powered muscle
tissue was further homogenized using a PRO200 homogenizer (PRO Scientific Inc) and RNA
was extracted with TRIzol reagent (Invitrogen). Potential residual genomic DNA was elimi-
nated using the Turbo DNA-free Kit (Ambion) and 1μg of DNAse-treated RNA was retrotran-
scripted using the Superscript First Strand kit (Invitrogen). Quantitative real-time PCR
(qRT-PCR) was performed from 1:10 diluted cDNA in triplicates using StepOne Plus Real-
Time PCR System (Applied Biosystems). The gene-specific TaqMan probes (Applied Biosys-
tems) used are indicated in Table 1. Geometric mean of the reference genes Gapdh and Actb
(β-actin) was used for normalization [15] and relative gene expression was determined using
the 2-ΔΔCT method [16].
Protein expression
Powdered tissue (see above) was homogenized in RIPA lysis buffer containing protease inhibi-
tors (Roche). The homogenate was centrifuged at 10000 ×g for 10 min at 4˚C, the supernatant
was collected and the protein concentration was determined by BCA method (Sigma Aldrich).
Forty micrograms of total protein were subjected to SDS/PAGE and transferred to PVDF
membranes (Amersham Biosciences). For immunodetection, membranes were blocked over-
night in 5% skimmed milk at 4˚C and then incubated one hour with the primary antibody
anti-hSOD1 (HPA001401 Sigma-Aldrich). After washes, the membranes were incubated with
HRP-conjugated anti-rabbit secondary antibody (sc-2004 Santa Cruz 1:3000), washed again
and finally incubated with enhanced chemiluminescent reagent (GE Healthcare Life Science).
Table 1. Taqman gene expression assays used in the study.
Gene Symbol Part Number
Ankrd1 Mm00496512_m1
Col19a1 Mm00483576_m1
Gsr Mm00833903_m1
Mt2 Mm00809556_s1
Myog Mm00446194_m1
Snx10 Mm00511049_m1
Bax Mm00432050_m1
Bcl2 Mm00477631_m1
Casp1 Mm00438023_m1
Casp3 Mm01195085_m
Atg5 Mm00504340_m1
Becn1 Mm00517174_m1
E2f1 Mm00432939_m1
Map1lc3a Mm00458724_m1
p62/Sqstm1 Mm00448091_m1
Actb 4352933E
Gapdh 4352932E
https://doi.org/10.1371/journal.pone.0210752.t001
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Immunoblots were exposed and scanned, and quantitative densitometry was performed with
AlphaEaseFC software (Bonsai).
Electrophysiological tests
SOD1G93A mice were injected with 5-FU (n = 6) or saline (n = 6) as indicated above and
motor nerve conduction tests were performed before the first injection (at the age of 10 weeks)
and at the age of 12 (one injection), 14 (two injections) and 16 (three injections) weeks. The
sciatic nerve was stimulated and the compound muscle action potential (CMAP) from tibialis
anterior and plantar interossei miscles was recorded as previously described [17].
Histological and immunohistochemical processing
After the last electrophysiological tests at the age of 16 weeks, mice were transcardially per-
fused with 4% paraformaldehyde in PBS (Gibco) and the lumbar segment of the spinal cord
was removed. After post-fixation and cryopreservation, transverse sections (40 μm) were seri-
ally cut with a cryotome (CM190, Leica Microsystems) between L3 and L5 segmental levels.
MN count was performed as previously described [18]. For immunohistochemistry, sections
were blocked with PBS-triton fetal bovine serum (Sigma Aldrich) and incubated overnight
with primary antibodies for anti-glial fibrillary acidic protein (GFAP 1:1000, Dako) or rabbit
anti-ionized calcium binding adaptor molecule 1 (Iba11:1000, Wako). After washing with PBS,
sections were incubated with Alexa Fluor 488- or 594-conjugated secondary antibody for one
hour at room temperature (1:200, Jackson Immunoresearch). Astroglial and microglial inmu-
noreactivity quantification was performed as previously described [17].
Statistical analysis
Statistical analysis for behavioral assays, electrophysiology tests, cell proliferation and gene
expression was performed by means of ANOVA or Student´s t-test. Survival over time was
computed using Kaplan-Meier estimates and the survival distributions (as well as disease
onset) of treated vs non-treated animals were tested with Mantel-Cox log-rank test. Values
were considered statistically significant (�) at P<0.05. Tendency (^) towards significance at
P<0.1 is indicated in some cases.
Results
The effect of 5-FU administration on peripheral blood and bone marrow
Granulocyte colony stimulating factor (GCSF) and its analog Pegfilgrastim increase the mobi-
lization of hematopoietic stem cells and blood WBC count [6, 7]. Initially, our aim was to use
5-FU as an opposite treatment compared to GCSF. To confirm the expected action of 5-FU,
we measured the effect of 5-FU administration on the number of the circulating white blood
cells (WBC) in the SOD1G93A mice following the treatment with a single dose of 5-FU at 150
mg/kg. Hemograms were performed at 4, 14 and 20 days after 5-FU administration (t = 4,
t = 14, t = 20) and compared with baseline counts before the treatment (t = 0) (Fig 1). At t = 0,
all the measured parameters were within the expected physiological values. In agreement with
earlier studies that used the same dosage and delivery route [19], we obtained the minimum
values for total WBCs (Fig 1A), lymphocytes (Lym, Fig 1B), monocytes (MID, Fig 1C) and
granulocytes (Gra, Fig 1D) four days after 5-FU administration. This reduction was rapidly
recovered by the proliferative capacity of the bone marrow since the levels of circulating WBC
(Fig 1A) and BMMC of the bone marrow (Fig 1E) reached physiological values at day 14 and
20. The number of red blood cells, hemoglobin and the hematocrit maintained within
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physiological levels and were not affected by 5-FU (S1 Fig). However, in agreement with previ-
ous studies [20], 5-FU administration promoted a strong temporal increase in the number of
platelets 14 days after treatment (Fig 1F).
Homeostasis of the hematopoietic system can be maintained by a rapid response to the loss
of progenitors to restore the steady-state. Using flow cytometry analysis, a rapid decline in cir-
culating hematopoietic stem cells (HSC, Fig 2A) and common myeloid precursors (CMP, Fig
Fig 1. Long-term hematologic alterations in SOD1G93A mice in response to single 5-FU administration. Blood samples were analyzed before 5-FU
treatment (0 days) and up to 20 days after 5-FU administration. (A) Total WBC, (B) lymphocytes, (C) monocytes (mid-range absolute count, MID) and (D)
granulocytes are expressed as number of cells x109 per ml of blood. (F) Bone marrow cellularity expressed BMMC x 106 per femur and (E) platelets (PLT) as
number of cells x109 per ml of blood. Data is shown as mean (n = 4, except day 20 n = 2) +/- SEM. The asterisk (�) and the hash (#) denote significance
compared with pre-treatment and with t = 4, respectively. One way ANOVA with Tukey’s test, �/# p<0.05, ��/## p< 0.01.
https://doi.org/10.1371/journal.pone.0210752.g001
Fig 2. Circulating hematopoietic stem cells in SOD1G93A mice after fortnightly 5-FU administration. Data is shown as the mean fold change +/- SEM in
the percentage of (A) HSC, (B) CMP and (C) CLP in 5-FU treated SOD1G93A mice compared with the mean of vehicle-treated SOD1G93A mice (n = 10 per
group). Day 65 are the pre-treatment samples and days 75, 90 and 105 are each taken after 4 days from last 5-FU administration. �p<0.05.
https://doi.org/10.1371/journal.pone.0210752.g002
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2B) was observed. Similar, although statistically insignificant pattern was observed in common
lymphoid precursors (CLP, Fig 2C). However, in two weeks following an intraperitoneal 5-FU
administration at 150 mg/kg, the levels of circulating and bone marrow WBC, as well as circu-
lating HSC were restored to basal levels. These results prompted us to investigate a treatment
regimen for the behavioural and lifespan studies, in which 5-FU at 150 mg/kg was delivered
once every two weeks.
Low-dose 5-FU administration prolongs life span and improves locomotor
function in SOD1G93A mice
SOD1G93A mice have a shortened lifespan and show progressive locomotor defects during
the symptomatic stage of the disease. 5-FU administration was initiated at the age of 70 days, a
late presymptomatic stage in which SOD1G93A mice do not yet show overly clinical features
(such as weight loss or impaired locomotory function) but electrophysiological abnormalities
can be detected [17]. It was found that fortnightly intraperitoneal 5-FU injections at 150 mg/
kg delayed the median onset of the disease (controls 82 days and 5-FU treated 117 days, log-
rank test p<0.01) as measured by initiation of the weight loss (Fig 3A). In the same line,
median lifespan of 5-FU treated mice was significantly prolonged (controls 127 days and 5-FU
treated 137 days, log-rank test p<0.001) (Fig 3B). The effects of 5-FU administration on motor
coordination and grip strength were tested by means of rotarod and hang wire tests, respec-
tively. On the rotarod (Fig 3C), vehicle control SOD1G93A mice started to decline in perfor-
mance at the age of 103 days, whereas all 5-FU treated mice were still able to properly perform
the test (p<0.05). From this age, 5-FU treated mice performed significantly better on the
rotarod at 117 and 124 days (p<0.05) compared to untreated littermates, showing a delay in
the progression of the disease. Muscle strength, assessed by hang-wire test, was not signifi-
cantly affected although a close to significant positive effect of 5-FU was observed at late stage
of the disease (age of 124 days, p = 0.06) (Fig 3D). Body weight was recorded weekly (Fig 3E).
Besides a slight (non-significant) weight loss after the first administration, 5-FU treated mice
recovered the following week and exhibited generally milder mutant SOD1-associated weight
loss in the symptomatic stage compared to untreated mice. From 117 to 131 days, the vehicle
control group lost more than 10% of body weight whereas 5-FU -treated group conserved
their initial weight until 124 days (p<0.05). Together, the above data indicates that 5-FU exerts
a therapeutic effect on the progression of the disease as it prolongs life span, improves the loco-
motor behavior and delays terminal weight loss of the ALS mice.
5-FU does not protect motor neurons or reduce reactive gliosis in
SOD1G93A mice
Distal axonal degeneration initiates early during the disease, before the death of MN cell bod-
ies, in ALS patients and in animal models of the disease [21]. Lower MN functional state was
assessed by motor nerve conduction tests between 8 and 16 weeks of age. No significant differ-
ences were found in the amplitude of CMAPs in 5-FU treated vs. vehicle group in plantar (Fig
4A) or tibialis anterior (TA, Fig 4B) muscles although 5-FU administration had a marginal
effect on TA CMAP from 10 to 14 weeks. MN counts in the lateral ventral horns of lumbar spi-
nal cord sections revealed almost 50% loss in SOD1G93A mice compared with their wild-type
littermates at 16 weeks of age (Fig 4C). 5-FU treatment did not improve sparing of MNs as
they were lost equally in both treated and non-treated SOD1G93A mice (Fig 4D). Chrna1
(cholinergic receptor, nicotinic, alpha 1) and Rrad (Ras-related associated with diabetes),
genes whose expression levels are upregulated by denervation and in SOD1G93A animals [22–
25], were not significantly affected by 5-FU (Fig 4D).
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Next, immunofluorescence was performed against GFAP and Iba1, markers for astrocytes
and microglia, respectively, to analyze reactive glial response in the spinal cord. SOD1G93A
mice from both treated and non-treated groups showed an evident increase of astrocytosis and
Fig 3. 5-FU increases lifespan, improves rotarod performance and mitigates weight loss of SOD1G93A mice. SOD1G93A mice were treated
with 5-FU every two weeks starting at age of 70 days. In each graph, groups of 5-FU treated (dark grey) and control (light grey) SOD1G93A mice
are shown. (A) Cumulative probability of the onset of disease, controls 82 days and 5-FU treated 117 days (log-rank test p = 0.027). (B) Cumulative
probability of survival, controls 127.5 days and 5-FU treated 137 days (log-rank test p = 0.0003). Latency to falling when submitted to the (C)
rotarod or (D) hang-wire test. (E) Relative weight evolution during the disease progression. � p< 0.05; ^p<0.1 (tendency). Note that the X-axes for
the panels A and B are cut for clarity.
https://doi.org/10.1371/journal.pone.0210752.g003
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microgliosis (Fig 5). Quantification of the immunoreactivity demonstrated that 5-FU treat-
ment did not modulate the reactive gliosis in SOD1G93A mice. The above data suggests that
5-FU does neither lead to spinal MN protection nor reduce reactive gliosis, and its possible
therapeutic effect should be based on other mechanisms of action.
Fig 4. Electrophysiology and motor neuron (MN) survival. Lower motor function was evaluated in (A) plantar and (B) tibialis
anterior (TA) muscles at 8–16 weeks of age in non-treated (control, light grey) and 5-FU treated (5-FU, dark grey) SOD1G93A mice
by measuring the amplitude of the CMAP. Values are means (n = 6 per group) +/- SEM. (C) Representative images of Nissl stained
L4 spinal cord sections from wild-type (WT), non-treated (SOD1 Control) and 5-FU treated (SOD1 5-FU) SOD1G93A mice at age
of 16 weeks. Scale bar 100 μm. (D) Number of MN counted per spinal cord section in WT (white bars), non-treated (SOD1 control,
light grey bars) and 5-FU (SOD1 5-FU, dark grey bars) SOD1G93A mice. Data are shown as mean of sections counted from each
mouse (n = 7 for wt, 10 per group for SOD1G93A) ± SEM. (E) Relative quantification of Chrna1 and Rrad transcript levels in wild-
type (WT), non-treated (control) and 5-FU treated (5-FU) SOD1G93A mice at age of 15 weeks. One way ANOVA with Tukey’s
test, �� p<0.001, ��� p<0.0001.
https://doi.org/10.1371/journal.pone.0210752.g004
5-FU improves ALS mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0210752 January 14, 2019 9 / 16
5-FU does not ameliorate commonly elevated SOD1G9A muscle markers
To search for molecular evidence, we analyzed the expression of genes involved in muscle
homeostasis and metabolism that were previously shown to be induced in the SOD1G93A
mice [23, 24]. As expected, in symptomatic mutant mice at 15 weeks of age, the expression of
Ankrd1, Col19a1, GSr, Mt2, Myog and Snx10 were upregulated compared to their wild-type lit-
termates (Fig 6A). However, there were no differences observed between 5-FU treated and
control SOD1G93A animals besides a tendency for reduced expression of Gsr (glutathione
reductase) and Snx10 (sortin nexin 10) (p<0.1). Equally, apoptotic markers Bax (BCL2-asso-
ciated X protein) and Casp3 (Caspase 3), as well as autophagy markers Lc3 (Map1lc3a) and p62
(Sqstm1), were all upregulated in both untreated and 5-FU-treated SOD1G93A muscles com-
pared with wild type (Fig 6B and 6C). Hence, the above data suggests that, at least at transcript
level, there is no major effect by 5-FU on myogenic, apoptotic or autophagic markers com-
monly elevated in SOD1G9A muscles.
Fig 5. Analysis of glial reactivity in SOD1G93A mice. (A) Representative microphotographs of spinal cord ventral horns from
wild type, control SOD1G93A and 5FU treated SOD1G93A mice immunolabelled with markers for astrocytes (GFAP) and
microglia (Iba1). Scale bar 125 μm. (B) Histograms representing the quantification of GFAP and Iba1 immunoreactivity in vehicle
control (SOD1 control, light grey bars) and 5-FU treated (SOD1 5-FU, dark grey bars) SOD1G93A mice compared to wild-type
(WT, white bars) mice. The integrated density (ID) is the area above the threshold for the mean density minus the background.
One way ANOVA with Tukey’s test, �� p<0.001, ��� p<0.0001.
https://doi.org/10.1371/journal.pone.0210752.g005
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Discussion
The results of the present study indicate that treatment with a low dose of 5-FU increases the
lifespan, delays the disease onset and slightly improves the motor performance of the
SOD1G93A mice. Although we were not able to demonstrate the cellular targets behind the
beneficial effect of 5-FU, we shall next discuss the potential importance of the findings suggest
further studies in order to address the mechanistic basis of the drug effect in the ALS model.
Analogs of granulocyte colony stimulating factor (GCSF) are used in clinic to treat neutro-
penia in patients receiving myelosuppressive drugs. GCSF stimulates hematopoietic precursors
of the bone marrow as well as hematopoietc stem cell (HSC) mobilization to the bloodstream.
Long term treatment with GCSF analog pegfilgrastim attenuates reactive gliosis and increases
survival of SOD1G93A mice [6], possibly increasing turnover of microglia and infiltration of
monocytes into peripheral tissues to modulate ALS-associated inflammatory response. Here,
the rationale for testing 5-FU in a mouse model of ALS was to investigate an agent that has an
opposite effect on peripheral WBC and HSC. A single dose of 5-FU eliminates the majority of
Fig 6. Gene expression profile in skeletal muscle. The graphics show the fold change in transcript levels in non-treated SOD1G93A muscles (gray
bars) and 5-FU treated SOD1G93A muscles (dashed bars) compared with their respective wild-type littermates (white bars) at 105 days of age. (A) Fold
change in the transcript levels of Ankrd1, Col19a1, Gsr, Mt2, Myog and SNx10. (B) Fold change in the expression of the apoptotic regulators Bax,Blc2,
Casp1 and Casp3. (C) Transcript levels of the autophagy mediator´s genes Atg5, Beclin, E2F1, LC3, and p62. Data are shown as mean values ± SEM.
�p<0.05; ��p<0.001; ^ p<0.1 (tendency).
https://doi.org/10.1371/journal.pone.0210752.g006
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the hematopoietic system, i.e. cells that are actively dividing. However, quiescent, most primi-
tive stem cells are saved, triggered to cycle and reconstitute the whole hematopoietic system
within 2 weeks of 5-FU administration [26, 27]. This is in line with our data since we found
that peripheral and bone marrow WBC were completely recovered in two weeks, when the
next dose of 5-FU was administered.
Although the short-term effects of 5-FU on circulating WBC and HSC was negative, the
long-term treatment may also induce beneficial effects. In a study on HSC ageing, [28]
12-week-old mice were injected with 5-FU using a similar treatment regime (150 mg/kg IP,
once in three weeks). After the initial drop, the long term assessment revealed that HSC subset
was increased after the last 5-FU treatment (2 to 4 treatments). However, these cells were func-
tionally challenged due epigenetic alterations, apparently caused by an increased number of
cell duplications [28]. Thus, forcing the quiescent stem cells to replicate with low-dose 5-FU
pulses may have beneficial effects. However, the possibility that the treatment promotes ageing
of the stem cell populations needs to be considered. For this reason, it would be important to
first determine the minimal effective concentration of 5-FU. Secondly, combined treatment
strategies or related but less toxic substances should be investigated. These could include com-
bined treatments with agents that optimize TS binding of 5-FU (leucovorin), enhance 5-FU
bioavailability and activation (Uracil/Ftorafur, Methotrexate) or 5-FU prodrugs that allow
alternative delivery route and side-effect minimization (Capecitabine, Tegafur).
Most 5-FU is metabolized, mainly in the liver, to 5-dihydrofluorouracil (DHFU) which in
turn, after further metabolic conversions, is secreted as 2-fluoro-beta-alanine (FBAL) through
the kidney. However, to be bioactive, i.e. to kill fast-replicating cells, 5-FU needs to be metabo-
lized via other route to fluorouridine monophosphate (FUMP) that can be further converted
to its active metabolites responsible for TS inhibition, DNA and RNA damage. It is possible
that some of the cellular consequences of 5-FU metabolites important for beating cancer cells
are also involved in the improvement of the phenotypic outcome in SOD1G93A mice. Cell
cycle inhibitors such as 5-FU block cell proliferation at high concentrations. At low concentra-
tions, however, they have been shown to promote proliferation of some cancer cells in vitro
[29]. This type of “hormetic dose–response” may be caused by a direct stimulation or after an
initial homeostatic disruption followed by an overcompensation response. Besides, stress at
low levels may elicit adaptive beneficial responses that may protect against subsequent expo-
sure to severe stress [30]. Oxidative stress is thought to play a major role in ALS pathogenesis
[31, 32]. Moreover, 5-FU is known for inducing oxidative stress in bone marrow, which is
involved in myelotoxicity in mice [33]. Therefore, it is feasible that mice receiving 5-FU at pre-
symptomatic stage will become pre-conditioned to better cope with the subsequent oxidative
stress insult caused by SOD1G93A expression.
5-FU is a fluorinated analog of uracil. Both 5-FU and uracil use the same transport mecha-
nism into cells. Uridine, a glycosylated uracil, is known to ameliorate the pathological pheno-
type of SOD1G93A mice [34]. As opposed to uridine experiment by Amante et al [34], we did
not observe MN preservation in 5-FU treated mice. However, we cannot discard the possiblity
of subtle changes in MN preservation or cell function. The spinal MN counts were carried out
at 16 weeks of age, so we may have potentially missed alterations in MN numbers and reactive
gliosis at earlier times. Therefore, further analysis is warranted on the effects of 5-FU in spinal
cord neurons at earlier stages of the symptomatic phase.
Based on the presented transcript and protein data, there is no difference in the expression
of SOD1G93A transgene in 5-FU vs. vehicle treated mice (S2 Fig). However, one of the most
feasible possibilities is that 5-FU may interfere with SOD1 misfolding or aggregation. Misfold-
ing can be transmitted between SOD1 molecules in cultured cells [35] and wild type SOD1 can
be misfolded by expression of mutant FUS or TDP43 (TARDBP) [36], products of genes also
5-FU improves ALS mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0210752 January 14, 2019 12 / 16
affected in ALS. Besides these intermolecular actions, misfolding can be tranferred intercellu-
larly between cells in culture [37]. Recently, 5-FU and 5-fluorouridine (5-Fur) has been shown
to effectively block the spread of SOD1 misfolding in propagated misfolding cell culture assays
[38]. Besides, 5-Fur has been shown to attenuate protein aggregation to the same extent as an
antibody detecting misfolded SOD1 [39]. Therefore, although in vivo data on possible direct
effects of 5-FU on SOD1 is missing, further evaluation of its potential effects on delaying dis-
ease propagation via antagonistic effect on misfolding and/or aggregation is warranted.
To conclude, the surprising finding that the anti-cancer drug 5-FU elicits protective effect
on SOD1G93A model of ALS puts 5-FU and similar antimetabolites in the group of agents
that could be possibly repurposed for the treatment of MN diseases. Studies focusing on target
tissues and cell types, as well as resolving the molecular mechanisms of action of these sub-
stances on ALS models are needed.
Supporting information
S1 Fig. The effect of 5-FU administration on red blood cells, hemoglobin and hematocrit.
Red blood cells (A), hemoglobin (B) and hematocrit (C) values are shown for pretreatment (0
days) and for 4, 14 and 20 days after 5-FU administration.
(TIF)
S2 Fig. The effect of 5-FU administration on hSOD1-G93A transgene expression. Expre-
sion of human SOD1 (hSOD1G93A) in mRNA (A) and protein (B) level in transgenic mice
treated with 5-FU (SOD1 5-FU) and in vehicle controls (SOD1 Control).
(TIF)
S1 File. Numerical data for the figures.
(XLSX)
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